At a glance
ClinicalIndex Comparison RecordN/ACompleted· 5,169 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
In Brief
An observational study for Antiretroviral Toxicity. Completed, enrolled 5,169 participants across 22 sites in 2 countries.
Detailed Summary
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAntiretroviral Toxicity
CountriesPuerto Rico, United States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Drug Abuse (NIDA), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Mental Health (NIMH), National Heart, Lung, and Blood Institute (NHLBI), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute of Neurological Disorders and Stroke (NINDS), Tulane University School of Medicine, National Institute of Dental and Craniofacial Research (NIDCR), NIH Office of AIDS Research (OAR)
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedMar 2011
Primary CompletionMay 2025
TodayJul 2026
First PostedMar 7, 2011
Enrollment StartMar 1, 2007
Primary CompletionMay 31, 2025
TodayJul 2, 2026
Enrollment to primary: 18.3 yearsPosted 15.3 years ago